SK11982002A3 - Nová protilátka so špecificitou pre rakovinu hrubého čreva - Google Patents
Nová protilátka so špecificitou pre rakovinu hrubého čreva Download PDFInfo
- Publication number
- SK11982002A3 SK11982002A3 SK1198-2002A SK11982002A SK11982002A3 SK 11982002 A3 SK11982002 A3 SK 11982002A3 SK 11982002 A SK11982002 A SK 11982002A SK 11982002 A3 SK11982002 A3 SK 11982002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- binding structure
- binding
- tumor
- cells
- phage
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0000597A SE0000597D0 (sv) | 2000-02-24 | 2000-02-24 | Novel antibody |
PCT/SE2001/000395 WO2001062286A1 (en) | 2000-02-24 | 2001-02-23 | Novel antibody with specificity for colon cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SK11982002A3 true SK11982002A3 (sk) | 2003-03-04 |
Family
ID=20278567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1198-2002A SK11982002A3 (sk) | 2000-02-24 | 2001-02-23 | Nová protilátka so špecificitou pre rakovinu hrubého čreva |
Country Status (22)
Country | Link |
---|---|
US (1) | US7425623B2 (ko) |
EP (1) | EP1257291A1 (ko) |
JP (1) | JP2003523213A (ko) |
KR (1) | KR20020079888A (ko) |
CN (1) | CN1406136A (ko) |
AU (1) | AU775876B2 (ko) |
BR (1) | BR0108609A (ko) |
CA (1) | CA2400661A1 (ko) |
EE (1) | EE200200473A (ko) |
HK (1) | HK1052648A1 (ko) |
HU (1) | HUP0300007A3 (ko) |
IL (1) | IL151325A0 (ko) |
MX (1) | MXPA02008315A (ko) |
NO (1) | NO20023670L (ko) |
NZ (1) | NZ520523A (ko) |
PL (1) | PL356386A1 (ko) |
RU (1) | RU2268068C2 (ko) |
SE (1) | SE0000597D0 (ko) |
SK (1) | SK11982002A3 (ko) |
WO (1) | WO2001062286A1 (ko) |
YU (1) | YU63702A (ko) |
ZA (1) | ZA200206039B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2450692A1 (en) * | 2001-06-12 | 2003-01-30 | Kyogo Itoh | Tumor antigen |
US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
CN1303105C (zh) * | 2003-12-08 | 2007-03-07 | 陈志南 | 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用 |
WO2007146172A2 (en) * | 2006-06-07 | 2007-12-21 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
EP2048241B1 (en) * | 2007-10-08 | 2012-07-25 | Sividon Diagnostics GmbH | Method employing GAPDH as molecular markers for cancer prognosis |
DK2245063T3 (en) * | 2007-12-18 | 2015-12-07 | Bioalliance Cv | Antibodies that recognize carbohydrate AN EPITOPE ON CD-43 AND CEA expressed CANCER CELLS AND PRACTICES BY WHICH THEY USED |
WO2010023917A1 (ja) * | 2008-09-01 | 2010-03-04 | 国立大学法人名古屋大学 | 抗がん剤の作用増強剤及びその利用、並びにがん患者の予後推定用バイオマーカー及びその利用 |
FR2945952B1 (fr) * | 2009-05-27 | 2013-10-04 | Univ Claude Bernard Lyon | Anticorps anti-ck8 pour utilisation comme medicament. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5798257A (en) * | 1990-07-09 | 1998-08-25 | Research Corporation Technologies, Inc. | Nucleic acid encoding human MTS-1 protein |
US5994088A (en) * | 1991-03-08 | 1999-11-30 | Board Of Trustees Of The University Of Illinois | Methods and reagents for preparing and using immunological agents specific for P-glycoprotein |
EP0656788B1 (en) * | 1992-08-07 | 2006-10-18 | Pharmexa Inc. | Hla binding peptides and their uses |
US5972643A (en) * | 1994-06-17 | 1999-10-26 | Fred Hutchinson Cancer Research Center | Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor |
US6140470A (en) * | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
IL125073A0 (en) * | 1996-01-08 | 1999-01-26 | Genentech Inc | Wsx receptor and ligands |
WO1998003411A1 (fr) | 1996-07-18 | 1998-01-29 | Montania | Bouchon avec recipient auxiliaire et procede de realisation |
DE69718341T2 (de) * | 1996-10-08 | 2003-10-30 | Bisys B V U | Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül |
SE9700291D0 (sv) * | 1997-01-31 | 1997-01-31 | Pharmacia & Upjohn Ab | Selection method and prodcts resulting therefrom |
CA2288600C (en) * | 1997-05-02 | 2010-06-01 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
WO1999010485A1 (en) * | 1997-08-29 | 1999-03-04 | Selective Genetics, Inc. | Methods using phage display for selecting internalizing ligands for gene delivery |
DE19739525A1 (de) * | 1997-09-09 | 1999-09-30 | Heinrich Abbrederis | Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen |
EP0934953A2 (en) * | 1997-12-03 | 1999-08-11 | Boehringer Mannheim Corporation | Complex specific antibodies, method of preparation and uses thereof |
AU770952B2 (en) * | 1999-03-01 | 2004-03-11 | Genentech Inc. | Antibodies for cancer therapy and diagnosis |
-
2000
- 2000-02-24 SE SE0000597A patent/SE0000597D0/xx unknown
-
2001
- 2001-02-23 AU AU36294/01A patent/AU775876B2/en not_active Ceased
- 2001-02-23 PL PL01356386A patent/PL356386A1/xx not_active Application Discontinuation
- 2001-02-23 HU HU0300007A patent/HUP0300007A3/hu unknown
- 2001-02-23 KR KR1020027010963A patent/KR20020079888A/ko not_active Application Discontinuation
- 2001-02-23 US US10/182,132 patent/US7425623B2/en not_active Expired - Fee Related
- 2001-02-23 NZ NZ520523A patent/NZ520523A/en unknown
- 2001-02-23 EE EEP200200473A patent/EE200200473A/xx unknown
- 2001-02-23 EP EP01908551A patent/EP1257291A1/en not_active Withdrawn
- 2001-02-23 JP JP2001561350A patent/JP2003523213A/ja not_active Withdrawn
- 2001-02-23 CN CN01805577A patent/CN1406136A/zh active Pending
- 2001-02-23 MX MXPA02008315A patent/MXPA02008315A/es unknown
- 2001-02-23 YU YU63702A patent/YU63702A/sh unknown
- 2001-02-23 BR BR0108609-0A patent/BR0108609A/pt not_active IP Right Cessation
- 2001-02-23 SK SK1198-2002A patent/SK11982002A3/sk not_active Application Discontinuation
- 2001-02-23 WO PCT/SE2001/000395 patent/WO2001062286A1/en active IP Right Grant
- 2001-02-23 CA CA002400661A patent/CA2400661A1/en not_active Abandoned
- 2001-02-23 RU RU2002125386/15A patent/RU2268068C2/ru not_active IP Right Cessation
- 2001-02-23 IL IL15132501A patent/IL151325A0/xx unknown
-
2002
- 2002-07-29 ZA ZA200206039A patent/ZA200206039B/en unknown
- 2002-08-02 NO NO20023670A patent/NO20023670L/no not_active Application Discontinuation
-
2003
- 2003-07-09 HK HK03104939.3A patent/HK1052648A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0300007A2 (en) | 2003-05-28 |
EP1257291A1 (en) | 2002-11-20 |
JP2003523213A (ja) | 2003-08-05 |
HUP0300007A3 (en) | 2005-11-28 |
IL151325A0 (en) | 2003-04-10 |
CA2400661A1 (en) | 2001-08-30 |
PL356386A1 (en) | 2004-06-28 |
CN1406136A (zh) | 2003-03-26 |
AU3629401A (en) | 2001-09-03 |
RU2002125386A (ru) | 2004-03-20 |
NO20023670D0 (no) | 2002-08-02 |
WO2001062286A1 (en) | 2001-08-30 |
BR0108609A (pt) | 2002-11-19 |
SE0000597D0 (sv) | 2000-02-24 |
MXPA02008315A (es) | 2002-12-09 |
AU775876B2 (en) | 2004-08-19 |
US20030176661A1 (en) | 2003-09-18 |
EE200200473A (et) | 2004-02-16 |
RU2268068C2 (ru) | 2006-01-20 |
KR20020079888A (ko) | 2002-10-19 |
YU63702A (sh) | 2006-01-16 |
US7425623B2 (en) | 2008-09-16 |
NZ520523A (en) | 2004-08-27 |
ZA200206039B (en) | 2003-07-29 |
NO20023670L (no) | 2002-08-23 |
HK1052648A1 (zh) | 2003-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7189816B1 (en) | Compounds | |
EP2215121B1 (en) | Anti-mesothelin antibodies and uses therefor | |
JP5904478B2 (ja) | 腫瘍において示差的に発現する遺伝子産物およびその利用 | |
KR101683884B1 (ko) | 항-EpCAM 항체 및 이의 용도 | |
JP2008505645A (ja) | ガン細胞に特異的な抗体を見出すための方法およびそれによって見出される抗体 | |
CZ294425B6 (cs) | Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor | |
US6346249B1 (en) | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products | |
CN106916227B (zh) | 一种tpbg抗体及其制备方法、其偶联物和应用 | |
KR20050037478A (ko) | Mn 결합 및 세포 부착-중화 활성을 갖는 인간 항체 | |
SK11982002A3 (sk) | Nová protilátka so špecificitou pre rakovinu hrubého čreva | |
KR101098186B1 (ko) | 피에이유에프(pauf) 특이적인 인간 단일클론항체, 이를 포함하는 암 치료용 조성물, 이를 이용하는 암의 진단방법 | |
JP2003527334A (ja) | A33抗原特異的免疫グロブリン産物を用いるa33抗原を発現する癌の影響を低減する方法 | |
EP4174086A1 (en) | Antibody specifically binding to lgals3bp, and use thereof | |
AU762240B2 (en) | Melanoma associated antigen (HMW-MAA) defined by a monoclonal antibody | |
US20150203582A1 (en) | Method of generating antibodies | |
KR20220002098A (ko) | Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도 | |
KR101551696B1 (ko) | Tm4sf5에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 | |
Casey et al. | Cambridge Healthtech Institute’s 4th Annual Recombinant Antibodies Conference |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC9A | Refused patent application |